A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy. Materials and Methods Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy. Results After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%. Conclusion Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.
Abstract
Purpose This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy. Materials and Methods Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy. Results After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%. Conclusion Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.
참고문헌 (28)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
- "SEER Cancer stat facts: stomach cancer" (2023)[URL]
- Kim NK, "A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer", Cancer, 71, pp.3813~3818 (1993)
- Van Cutsem E, "Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer : a report of the V325 Study Group", J Clin Oncol, 24, pp.4991~4997 (2006)
- Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer", N Engl J Med, 358, pp.36~46 (2008)
- Kang YK, "Capecitabine", cisplatin versus 5-fluorouracil, Ann Oncol, pp.2009, 20[DOI]
- Ajani JA, "Multicenter phase III comparison of cisplatin", S-1 with cisplatin, J Clin Oncol, pp.2010, 28[DOI]
- Al-Batran SE, "Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin : a study of the Arbeitsgemeinschaft Internistische Onkologie", J Clin Oncol, 26, pp.1435~1442 (2008)
- Koizumi W, "S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial) : a phase III trial", Lancet Oncol, 9, pp.215~221 (2008)
- Lee KW, "Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer(SOPP trial)", Gastric Cancer, 24, pp.156~167 (2021)
- Lee KW, "Populationbased outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer", J Cancer Res Clin Oncol, 142, pp.687~697 (2016)
- Lee JL, "A randomised multicentre phase II trial of capecitabine vs S-1as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer", Br J Cancer, 99, pp.584~590 (2008)
- Hwang IG, "A multi-center, open-label, randomized phase III trial of firstline chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer", J Geriatr Oncol, 8, pp.170~175 (2017)
- Aaronson NK, "The European Organization for Research and Treatment of Cancer QLQ-C30 : a quality-of-life instrument for use in international clinical trials in oncology", J Natl Cancer Inst, 85, pp.365~376 (1993)
- Blazeby JM, "Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer", Eur J Cancer, 40, pp.2260~2268 (2004)
- Osoba D, "Interpreting the significance of changes in health-related quality-of-life scores", J Clin Oncol, 16, pp.139~144 (1998)
- Hall PS, "A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer(321GO)", Br J Cancer, 116, pp.472~478 (2017)
- Hall PS, "Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among Older and frail patients with advanced gastroesophageal cancer : the GO2 phase 3 randomized clinical trial", JAMA Oncol, 7, pp.869~877 (2021)
- Hutchins LF, "Underrepresentation of patients 65 years of age or older in cancer-treatment trials", N Engl J Med, 341, pp.2061~2067 (1999)
- Talarico L, "Enrollment of elderly patients in clinical trials for cancer drug registration : a 7-year experience by the US Food and Drug Administration", J Clin Oncol, 22, pp.4626~4631 (2004)
- Kemeny MM, "Barriers to clinical trial participation by older women with breast cancer", J Clin Oncol, 21, pp.2268~2275 (2003)
- Hurria A, "Geriatric oncology research in the cooperative groups : a report of a SIOG special meeting", J Geriatr Oncol, 1, pp.40~44 (2010)
- Hurria A, "Predicting chemotherapy toxicity in older adults with cancer : a prospective multicenter study", J Clin Oncol, 29, pp.3457~3465 (2011)
- Extermann M, "Predicting the risk of chemotherapy toxicity in older patients : the Chemotherapy Risk Assessment Scale for High-Age Patients(CRASH)score", Cancer, 118, pp.3377~3386 (2012)
- Kim JW, "Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy : Korean Cancer Study Group(KCSG)multicentre prospective study", Br J Cancer, 118, pp.1169~1175 (2018)
- Kanesvaran R, "Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer", J Clin Oncol, 29, pp.3620~3627 (2011)
- Soubeyran P, "Predictors of early death risk in older patients treated with first-line chemotherapy for cancer", J Clin Oncol, 30, pp.1829~1834 (2012)